Although efforts have been made to increase sharing of individual participant data from clinical trials, data from many oncology clinical trials that support FDA approval of anticancer therapies remain unavailable to researchers.
The findings, published in JAMA Oncology, suggest data accessibility could be improved if all data that support the FDA registration of treatment became available at the time of FDA approval, researchers noted.
